Collplant biotechnologies announces third quarter financial results for 2023

Received a $10 million milestone payment in the third quarter from partner, abbvie inc., for achieving a major milestone in the second quarter in accordance with the strategic collaboration agreement related to the clinical-phase dermal filler product candidate company is preparing to launch large-animal study with a commercial size breast implant by year-end cash and cash equivalents totaled $29 million as of september 30, 2023, representing an estimated cash runway of at least two years revenues of $10.7 million and operating loss of $2.4 million for the first nine months of 2023 conference call to be held on november 29, 2023, at 10:00 am u.s. et; dial-in information herein rehovot, israel , nov. 29, 2023 /prnewswire/ -- collplant biotechnologies (nasdaq: clgn), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, today announced financial results for the third quarter ended september 30, 2023, and provided a corporate update on its programs. "this quarter, we continued to steadily advance our programs with modest cash use," said collplant's chief executive officer, yehiel tal.
CLGN Ratings Summary
CLGN Quant Ranking